WG
WGSWW
GeneDx Holdings Corp.
$0.006400
-17.95%
$103.9K
No data for this timeframe.
Vol
Market Cap$103.9K
Cap SizeNano Cap
Inst. Holders1 funds
Inst. Value$112.00
Inst. Activity0 buys / 1 sells
SEC Reports2
Recent Activity
May 4, 2026
SEC
GeneDx reported Q1 2026 revenue of $102.3M (17% YoY growth but below $112.5M consensus) and an adjusted net loss of $8.2
8-K — Impact 8/10
Apr 29, 2026
SEC
Director Katherine Stueland filed a Form 144 to sell 16,415 shares of Class A Common Stock valued at approximately $1.04
144 — Impact 2/10
Inst.
UBS Group AG — NEAR_EXIT
377 shares ($41.00)
Inst.
UBS Group AG — TRIM
49,588 shares ($3.6K)
Latest Reports
BEARISH
8-K
8/10
GeneDx reported Q1 2026 revenue of $102.3M (17% YoY growth but below $112.5M consensus) and an adjusted net loss of $8.2
May 4, 2026
NEUTRAL
144
2/10
Director Katherine Stueland filed a Form 144 to sell 16,415 shares of Class A Common Stock valued at approximately $1.04
Apr 29, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| WELLS FARGO & COMPANY/MN | $112.00 | — |
1 institutional holders with $112.00 total value (2,366 shares) as of 2025-Q4. Top holders: WELLS.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | WELLS FARGO & COMPANY/MN | 2,366 | $112.00 | 100.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | NEAR_EXIT | 49,588 | 377 | -99.2% | $41.00 | 2025-Q3 |
| UBS Group AG | TRIM | 143,251 | 49,588 | -65.4% | $3.6K | 2025-Q2 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
2 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 1 neutral. Avg impact: 5.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.1B | 8.1% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.1B | 8.0% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.5B | 11.9% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.6B | 24.4% | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.